172 related articles for article (PubMed ID: 20663134)
1. HIF1alpha isoforms in benign and malignant prostate tissue and their correlation to neuroendocrine differentiation.
Monsef N; Soller M; Panagopoulos I; Abrahamsson PA
BMC Cancer; 2010 Jul; 10():385. PubMed ID: 20663134
[TBL] [Abstract][Full Text] [Related]
2. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
Monsef N; Helczynski L; Lundwall A; Påhlman S;
Prostate; 2007 Aug; 67(11):1219-29. PubMed ID: 17562539
[TBL] [Abstract][Full Text] [Related]
3. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues.
Simak R; Capodieci P; Cohen DW; Fair WR; Scher H; Melamed J; Drobnjak M; Heston WD; Stix U; Steiner G; Cordon-Cardo C
Histol Histopathol; 2000 Apr; 15(2):365-74. PubMed ID: 10809354
[TBL] [Abstract][Full Text] [Related]
4. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
[TBL] [Abstract][Full Text] [Related]
5. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
[TBL] [Abstract][Full Text] [Related]
6. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.
Qi J; Nakayama K; Cardiff RD; Borowsky AD; Kaul K; Williams R; Krajewski S; Mercola D; Carpenter PM; Bowtell D; Ronai ZA
Cancer Cell; 2010 Jul; 18(1):23-38. PubMed ID: 20609350
[TBL] [Abstract][Full Text] [Related]
7. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C
Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465
[TBL] [Abstract][Full Text] [Related]
8. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.
Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE
Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues.
Wei H; Desouki MM; Lin S; Xiao D; Franklin RB; Feng P
Mol Cancer; 2008 Jan; 7():7. PubMed ID: 18208603
[TBL] [Abstract][Full Text] [Related]
10. Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer.
Straub B; Müller M; Krause H; Schrader M; Miller K
Urology; 2003 Jul; 62(1):172-6. PubMed ID: 12837461
[TBL] [Abstract][Full Text] [Related]
11. Human pHyde is not a classical tumor suppressor gene in prostate cancer.
Porkka KP; Nupponen NN; Tammela TL; Vessella RL; Visakorpi T
Int J Cancer; 2003 Sep; 106(5):729-35. PubMed ID: 12866033
[TBL] [Abstract][Full Text] [Related]
12. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma.
Cordon-Cardo C; Koff A; Drobnjak M; Capodieci P; Osman I; Millard SS; Gaudin PB; Fazzari M; Zhang ZF; Massague J; Scher HI
J Natl Cancer Inst; 1998 Sep; 90(17):1284-91. PubMed ID: 9731735
[TBL] [Abstract][Full Text] [Related]
13. The expression and localisation of beta-nerve growth factor (beta-NGF) in benign and malignant human prostate tissue: relationship to neuroendocrine differentiation.
Paul AB; Grant ES; Habib FK
Br J Cancer; 1996 Dec; 74(12):1990-6. PubMed ID: 8980402
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
[TBL] [Abstract][Full Text] [Related]
15. Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer.
Harries LW; Perry JR; McCullagh P; Crundwell M
BMC Cancer; 2010 Jun; 10():315. PubMed ID: 20569440
[TBL] [Abstract][Full Text] [Related]
16. Immunoreactivity of ubiquitin in human prostate gland.
Bataineh ZM; Habbal O
Neuro Endocrinol Lett; 2006 Aug; 27(4):517-22. PubMed ID: 16892003
[TBL] [Abstract][Full Text] [Related]
17. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status.
Bonkhoff H
Prostate Suppl; 1998; 8():18-22. PubMed ID: 9690659
[TBL] [Abstract][Full Text] [Related]
19. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.
Lin B; Utleg AG; Gravdal K; White JT; Halvorsen OJ; Lu W; True LD; Vessella R; Lange PH; Nelson PS; Hood L; Kalland KH; Akslen LA
Clin Cancer Res; 2008 Mar; 14(5):1397-406. PubMed ID: 18316561
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence.
Ito T; Yamamoto S; Ohno Y; Namiki K; Aizawa T; Akiyama A; Tachibana M
Oncol Rep; 2001; 8(6):1221-4. PubMed ID: 11605036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
